{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Syringe+Placebo&page=2",
    "query": {
      "intervention": "Syringe Placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Syringe+Placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T18:18:48.740Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04586712",
      "title": "Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle Injury",
        "Recovery",
        "Pain Relief"
      ],
      "interventions": [
        {
          "name": "Active CBD",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Control (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 34,
      "start_date": "2021-03-01",
      "completion_date": "2024-03-21",
      "has_results": true,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-09-23T18:18:48.740Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04586712"
    },
    {
      "nct_id": "NCT04505436",
      "title": "Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "HM15211",
          "type": "DRUG"
        },
        {
          "name": "Placebo of HM15211",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 215,
      "start_date": "2020-07-31",
      "completion_date": "2026-07-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-23T18:18:48.740Z",
      "location_count": 48,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Chula Vista, California + 37 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505436"
    },
    {
      "nct_id": "NCT04347239",
      "title": "Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus Disease 2019"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Leronlimab (700mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 484,
      "start_date": "2020-04-16",
      "completion_date": "2022-06-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-09-23T18:18:48.740Z",
      "location_count": 18,
      "location_summary": "Alexander City, Alabama • Fullerton, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04347239"
    },
    {
      "nct_id": "NCT05332067",
      "title": "Omalizumab Before Onset of Exacerbations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma in Children",
        "Atopy",
        "Viral Upper Respiratory Infection"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 300,
      "start_date": "2022-05-01",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-09-23T18:18:48.740Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05332067"
    },
    {
      "nct_id": "NCT00362232",
      "title": "Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Placebo: tablet of Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Placebo: syringes of Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3148,
      "start_date": "2006-06",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2014-11-04",
      "last_synced_at": "2026-09-23T18:18:48.740Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00362232"
    },
    {
      "nct_id": "NCT00697099",
      "title": "Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Semuloparin sodium",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2326,
      "start_date": "2008-06",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2013-01-23",
      "last_synced_at": "2026-09-23T18:18:48.740Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00697099"
    },
    {
      "nct_id": "NCT07048314",
      "title": "Stem Cells for Erectile Dysfunction Post RALP",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Erectile Dysfunction",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR",
          "type": "DRUG"
        },
        {
          "name": "Placebo in the OR",
          "type": "DRUG"
        },
        {
          "name": "Placebo in clinic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "40 Years to 70 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2026-07-07",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-23T18:18:48.740Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07048314"
    },
    {
      "nct_id": "NCT01843790",
      "title": "A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "GCS-100",
          "type": "DRUG"
        },
        {
          "name": "Placebo, Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "La Jolla Pharmaceutical Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 120,
      "start_date": "2013-06",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2015-09-01",
      "last_synced_at": "2026-09-23T18:18:48.740Z",
      "location_count": 4,
      "location_summary": "Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01843790"
    },
    {
      "nct_id": "NCT01616524",
      "title": "Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C Virus (HCV)"
      ],
      "interventions": [
        {
          "name": "Pegylated interferon lambda (pegIFNλ)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated interferon alfa-2a (pegIFNα-2a)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Daclatasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 880,
      "start_date": "2012-07",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2015-10-09",
      "last_synced_at": "2026-09-23T18:18:48.740Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01616524"
    },
    {
      "nct_id": "NCT06708299",
      "title": "CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Pericarditis"
      ],
      "interventions": [
        {
          "name": "CardiolRx",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cardiol Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2025-04-07",
      "completion_date": "2026-10-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-23T18:18:48.740Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Irvine, California • La Jolla, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06708299"
    }
  ]
}